Innovation in the production process of veterinary drugs against leptospirosis and borreliosis (Q9935): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item) |
(Removed claims) |
||||||||||||||
| Property / EU contribution | |||||||||||||||
| |||||||||||||||
| Property / EU contribution: 7,500,000.0 Czech koruna / rank | |||||||||||||||
| Property / EU contribution | |||||||||||||||
| |||||||||||||||
| Property / EU contribution: 300,000.0 Euro / rank | |||||||||||||||
| Property / EU contribution: 300,000.0 Euro / qualifier | |||||||||||||||
| |||||||||||||||
| Property / EU contribution: 300,000.0 Euro / qualifier | |||||||||||||||
| |||||||||||||||
Revision as of 16:42, 3 March 2020
Project in Czech Republic financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Innovation in the production process of veterinary drugs against leptospirosis and borreliosis |
Project in Czech Republic financed by DG Regio |
Statements
30,000,000.0 Czech koruna
0 references
25 percent
0 references
19 November 2015
0 references
23 August 2018
0 references
1 October 2018
0 references
Bioveta, a.s.
0 references
49°18'9.65"N, 17°4'54.52"E
0 references
49°17'53.88"N, 17°6'21.31"E
0 references
68323
0 references
Předmětem projektu je inovace procesu výroby a kultivace vakcín proti leptospiróze a borelióze založená na pomnožení spirochet fermentační kultivací v průmyslovém bioreaktoru. Inovace procesu bude realizována formou zavedení nové technologie výroby antigenů. Inovace se týká celé řady přípravků (např. Biocan L, Biocan Novel L4, B BioBos L, BioBos L6, Biofel B, Biocan B, Borrelym). V rámci projektu bude pořízena technologie pro nový způsob výroby, a to bioreaktory, formulační kotel a ultrafiltr. a. (Czech)
0 references
The purpose of the project is to innovate the process of producing and cultivating vaccines against leptospirosis and borreliosis based on the multiplication of spirochet fermentation culture in an industrial bioreactor. The process of innovation will be realised through the introduction of new technology for producing antigens. Innovation covers a wide range of products (e.g.: Biocan L, Biocan Novel L4, B BioBos L, BioBos L6, Biofl B, Biocan B, Borrely). The project will produce a technology for a new method of production, namely bioreactors, a co-formulant and an ultra filteum. (English)
0 references
Identifiers
CZ.01.1.02/0.0/0.0/15_014/0004382
0 references